| Literature DB >> 36135844 |
Baramee Chanabodeechalermrung1, Tanpong Chaiwarit1, Sarana Rose Sommano2,3,4, Pornchai Rachtanapun3,4,5, Nutthapong Kantrong6,7, Chuda Chittasupho1,3, Pensak Jantrawut1,3,4.
Abstract
Composite bacterial cellulose (BC) based hydrogel with alginate (A) or pectin (P) or alginate and pectin was fabricated via a physical crosslinking technique using calcium chloride (CaCl2) solution and incorporated with polyhexamethylene biguanide (PHMB) as an effective antimicrobial drug by immersion method. After that, the physicochemical properties of all hydrogel formulations were characterized. The result showed that the formulations with PHMB performed better physicochemical properties than the hydrogel without PHMB. Fourier transform infrared spectroscopy (FT-IR) showed the interaction between PHMB and the carboxylic group of alginate and pectin. BC/A-PHMB hydrogel performed suitable mechanical strength, fluid uptake ability, water retention property, drug content, high integrity value, and maximum swelling degree. Moreover, in vitro cell viability of BC/A-PHMB hydrogel revealed high biocompatibility with human keratinocyte cell line (HaCaT) and demonstrated prolong released of PHMB in Tris-HCl buffer pH 7.4, while rapid release in phosphate buffer saline pH 7.4. BC/A-PHMB hydrogel demonstrated good anti-bacterial activity against S. aureus and P. aeruginosa. In conclusion, BC/A-PHMB hydrogel could be a potential dual crosslinked ion-based hydrogel for wound dressing with anti-bacterial activity.Entities:
Keywords: alginate; bacterial cellulose; crosslinking; hydrogel; pectin
Year: 2022 PMID: 36135844 PMCID: PMC9505295 DOI: 10.3390/membranes12090825
Source DB: PubMed Journal: Membranes (Basel) ISSN: 2077-0375
Composition of different hydrogels containing BC.
| Sample Code | Polymer Composition | Crosslinking Agent | Drug | |||
|---|---|---|---|---|---|---|
| 2% | 0.5% | 5% | 0.5% | Ca2+ | PHMB | |
| BC/A | + | + | − | − | + | − |
| BC/P | + | − | + | − | + | − |
| BC/A/P | + | − | − | + | + | − |
| BC/A-PHMB | + | + | − | − | + | + |
| BC/P-PHMB | + | − | + | − | + | + |
| BC/A/P-PHMB | + | − | − | + | + | + |
Thickness, diameter, and puncture strength of hydrogels containing BC.
| Formulation | Thickness | Diameter | Puncture Strength |
|---|---|---|---|
| BC/A | 3.55 ± 0.18 a | 31.28 ± 0.15 a | 3.18 ± 0.12 a |
| BC/P | 4.65 ± 0.09 b | 47.74 ± 0.29 b | 1.75 ± 0.10 b |
| BC/A/P | 4.16 ± 0.21 c | 35.16 ± 0.74 c | 2.51 ± 0.08 c |
| BC/A-PHMB | 3.21 ± 0.10 d | 26.32 ± 0.02 d | 3.52 ± 0.16 d |
| BC/P-PHMB | 4.38 ± 0.07 c | 47.03 ± 0.78 b | 2.15 ± 0.15 e |
| BC/A/P-PHMB | 3.41 ± 0.29 a,d | 26.68 ± 0.19 d | 4.50 ± 0.22 f |
For each test, average values with a different letter show significant difference. In contrast, average values with the same letter are not statistically different (p < 0.05).
Figure 1Cross section of sponges composed of BC and incorporated with or without PHMB using SEM at 50×.
Figure 2Equilibrium fluid content (a), water retention property (b) of hydrogels containing BC.
Integrity value and maximum swelling degree of hydrogels containing BC.
| Formulation | Integrity Value (%) | Maximum Swelling Degree (%) |
|---|---|---|
| BC/A | 0 | ND |
| BC/P | 31 ± 0.50 a | 309 ± 6.78 a |
| BC/A/P | 0 | ND |
| BC/A-PHMB | 55 ± 0.80 b | 407 ± 25.87 b |
| BC/P-PHMB | 49 ± 0.82 c | 348 ± 11.97 c |
| BC/A/P-PHMB | 50 ± 1.06 c | 353 ± 25.12 c |
For each test, average values with a different letter show significant difference. In contrast, average values with the same letter are not statistically different (p < 0.05). ND indicates that the value was not detected.
Figure 3Fourier-transform infrared spectroscopy (FTIR) spectra of A, P, BC, a physical mixture of A, P, and BC with or without PHMB and bacterial cellulose composite sponge formulations.
Drug content of BC/A-PHMB, BC/P-PHMB and BC/A/P-PHMB hydrogels.
| Formulation | Drug Content (%) |
|---|---|
| BC/A-PHMB | 101.97 ± 6.95 a |
| BC/P-PHMB | 98.10 ± 5.24 a |
| BC/A/P-PHMB | 98.08 ± 4.14 a |
For each test, the average values with the same letter are not statistically different (p > 0.05).
Figure 4PHMB release profile from BC/A-PHMB hydrogel in PBS and Tris-HCl buffer pH 7.4.
BC/A-PHMB released kinetic profile in various drug release models.
| Kinetic Models | Parameter | Buffer | |
|---|---|---|---|
| PBS | Tris-HCl | ||
| Zero-order | R2 | 0.8947 | 0.9645 |
| 15.8502 | 13.5530 | ||
| First-order | R2 | 0.8885 | 0.9011 |
| 0.2101 | 2.7454 | ||
| Higuchi | R2 | 0.9845 | 0.9979 |
| 61.4814 | 33.8163 | ||
| Korsmeyer-Peppas | R2 | 0.9648 | 0.9981 |
| 70.8349 | 31.8966 | ||
|
| 0.5906 | 0.5613 | |
Antibacterial activity of BC/A-PHMB against S. aureus and P. aeruginosa growth.
| Sample | Diameter of Inhibition Zone (mm) | |
|---|---|---|
|
|
| |
| BC/A | ND | ND |
| 20% PHMB | 16.00 ± 0.22 a | 14.49 ± 0.48 a |
| BC/A-PHMB | 14.28 ± 0.31 b | 20.55 ± 1.53 b |
For each test, average values with different letters indicate a statistically significant difference (p < 0.05). ND is not detected.
Figure 5HaCaT cell viability after exposure to BC, PHMB, BC/A, BC/A-PHMB. The results are expressed as mean ± S.D. at a significant level of * p < 0.05 in comparison with BC/A.